Two scientific studies supporting the efficacy of InSea2, from innoVactiv, to beneficially affect post-meal blood sugar and insulin levels have been accepted for publication in peer-reviewed scientific journals.
 
The first publication features in vitro experiments showing the unique dual mechanism of action of InSea2 against amylase and glucosidase enzymes, as well as results demonstrating the carb-blocking effect of InSea2 in laboratory animals. These results were accepted for publication in Food Research International, a journal of the Canadian Institute of Food Science and Technology.
 
The second publication presents results from a recent positive human clinical trial in which InSea2 significantly reduced post-meal blood glucose response by 48% and insulin secretion by 12% while increasing insulin sensitivity by 8%. The results, originally disclosed at the 2010 Experimental Biology meeting in Anaheim, CA, were accepted for publication in Applied Physiology, Nutrition, and Metabolism, the official journal of the Canadian Society for Exercise Physiology affiliated with the National Research Council Research Press. For further information: www.innovactiv.com